1. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia
    Maitane Umerez et al, 2018, Pharmacogenomics CrossRef
  2. MiRNA Dysregulation in Childhood Hematological Cancer
    Jaqueline Carvalho de Oliveira et al, 2018, IJMS CrossRef
  3. MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential
    Rajab Mardani et al, 2018, J Cell Physiol CrossRef
  4. MicroRNA as a diagnostic biomarker in childhood acute lymphoblastic leukemia; systematic review, meta-analysis and recommendations.
    Wafaa M. Rashed et al, 2019, Critical Reviews in Oncology/Hematology CrossRef
  5. miRNA deregulation in childhood acute lymphoblastic leukemia: a systematic review
    Angela Gutierrez-Camino et al, 2019, Epigenomics CrossRef
  6. Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia
    Piqiang Zhang et al, 2020, Eur J Med Res CrossRef
  7. MicroRNA-223 decreases cell proliferation, migration, invasion, and enhances cell apoptosis in childhood acute lymphoblastic leukemia via targeting Forkhead box O 1
    Chunyu Li et al, 2020 CrossRef
  8. Myeloid-derived suppressor cells and regulatory T cells share common immunoregulatory pathways-related microRNAs that are dysregulated by acute lymphoblastic leukemia and chemotherapy
    Mohamed Labib Salem et al, 2020, Human Immunology CrossRef
  9. Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
    Juliette Roels et al, 2020, Blood Cancer Discov CrossRef
  10. The comprehensive landscape of miR-34a in cancer research
    Sijing Li et al, 2021, Cancer Metastasis Rev CrossRef
  11. One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
    Antonia Kalushkova et al, 2021, Epigenomes CrossRef
  12. Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
    Ezzatollah Fathi et al, 2021, CGT CrossRef
  13. MiR‐363‐3p promotes prostate cancer tumor progression by targeting Dickkopf 3
    Li‐zhe Xu et al, 2022, Clinical Laboratory Analysis CrossRef